Clinical Trials Browser

INDUSTRY × Fanconi Anemia, Complementation Group D1 × Breast × Clear all

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Clinical Trials

ICEBERG 1

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors